Primum non nocere... Inhaled glucocorticosteroids in 2003;Primum non nocere... Les glucocorticostéroïdes inhalés en 2003

Revue de Pneumologie Clinique

Volumn 59, Issue 3, 2003, Pages 129-137

  Lacronique, J ^a  

^a Hôpital Cochin ^*  (France)

Author keywords

Administration; Aerosol (propellants); Anti asthmatic agents (administration dosage, adverse effects); Asthma (drug therapy); Glucocorticoids (topical, adverse effects); Human; Inhalation

Indexed keywords

BECLOMETASONE; BUDESONIDE; GLUCOCORTICOID;

ASTHMA; BONE GROWTH; BONE METABOLISM; DRUG BIOAVAILABILITY; DRUG EFFICACY; EYE DISEASE; FIRST PASS EFFECT; GLAUCOMA; HUMAN; LIPID SOLUBILITY; OSTEOPOROSIS; REVIEW; RISK BENEFIT ANALYSIS;

ADMINISTRATION, INHALATION; ADRENAL GLANDS; ADULT; ASTHMA; BIOLOGICAL AVAILABILITY; BONE DEVELOPMENT; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS;

EID: 0042565824     PISSN: 07618417     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Lacronique J. Primum non nocere. Les corticoïdes inhalés. Rev Pneumol Clin 1996;52:137-43.
2. Demoly P, Jaffuel D, Chung KF, Bousquet J, Michel FB, Godard P. Pharmacological specificities and modalities of prescriptions for corticoids for asthmatic adults. Presse Med 1996;25:2025-30.
3. Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma Allergy 1997;52(Suppl):1-34.
4. Kamada AK, Szefler SJ. How should inhaled glucocorticoids be compared? J Allergy Clin Immunol 1997;99:735-7.
5. Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf 2000;23:11-33.
6. Place VA, Velazquez JG, Burdick KH. Precise evaluation of topically applied corticosteroid potency. Modification of the Stoughton-McKenzie assay. Arch Dermatol 1970;101:531-7.
7. Dahlberg E, Thalen A, Brattsand R, Gustafsson JA, Johansson U, Roempke K, et al. Correlation between chemical structure, receptor binding and biological activity of some novel, highly active, 16-alpha, 17-alpha-acetal-substituted glucocorticoids. Mol Pharmacol 1984;25:70-8.
8. Hogger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994;59:597-602.
9. Smith CL, Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung 1998;48:956-60.
10. Stellato C, Atsuta J, Bickel CA, Schleimer RP. An in vitro comparison of commonly used topical glucocorticoid preparations. J Allergy Clin Immunol 1999;104:623-9.
11. Umland SP, Nahrebne DK, Razac S, Beavis A, Pennline KJ, Egan RW, et al.: The inhibitory effects of topically active glucocorticoids on IL-4, IL- 5 and interferon-gamma production by cultured primary CD4+ T cells. J Allergy Clin Immunol 1997;100:511-9.
12. Atsuta J, Plitt J, Bochner BS, Schleimer RP. Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids. Am J Respir Cell Mol Biol 1999;20:643-50.
13. Harding SM. The human pharmacology of fluticasone propionate. Respir Med 1990;84(Suppl A):25-9.
14. Affrime MB, Cuss F, Padhi D, Wirth M, Pai S, Clement RP, et al. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol 2000;40:1227-36.
15. Derendorf H, Daley-Yates PT, Pierre LN, Efthimiou J. Bioavailability and metabolism of mometasone furoate: pharmacology versus methodology. J Clin Pharmacol 2002;42:383-7.
16. Ryrfeldt A, Andersson P, Edsbacker S, Tonnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982;122(Suppl):86-95.
17. Andersson P, Ryrfeldt A. Biotransformation of the topical glucocorticoids budesonide and beclomethasone 17 alpha, 21-dipropionate in human liver and lung homogenate. J Pharm Pharmacol 1984;36:763-5.
18. Olsson B. Aerosol particle generation from dry powder inhalers: can they equal pressurized metered dose inhalers? J Aerosol Med 1995;8S:13-8.
19. Toogood JH, Baskerville J, Jennings B, Lefcoe NM, Johansson SA. Use of spacers to facilitate inhaled corticosteroid treatment of asthma. Am Rev Respir Dis 1984;129:723-9.
20. Wilson AM, Sims EJ, Orr LC, Lipworth BJ. Differences in lung bioavailability between different propellants for fluticasone propionate. Lancet 1999;354:1357-8.
21. Berg E. In vitro properties of pressurized metered dose inhalers with and without spacer devices. J Aerosol Med 1995;8S:3-10.
22. Harrison LI, Dahl DR, Cline A, Chang SF, MacHacek J, Nelson J, et al. Pharmacokinetics and dose proportionality of beclomethasone from three strengths of a CFC-free beclomethasone dipropionate metered-dose inhaler. Biopharm Drug Dispos 1997;18:635-43.
23. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998;12:1346-53.
24. Thompson PJ, Davies RJ, Young WF, Grossman AB, Donnell D. Safety of hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol. Respir Med 1998;92(Suppl):33-9.
25. Davies R, Leach C, Lipworth B, Shaw R. Asthma management with HFA-BDP (Qvar). Hosp Med 1999;60:263-70.
26. Cripps AL, Munro AJ, Boles MG. Pharmaceutical evaluation of a new HFA-based metered dose inhaler for fluticasone propionate. J Aerosol Med 1997;10:6-5.
27. Weiner P, Berar-Yanay N, Davidovich A, Magadle R. Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate. Chest 1999;116:931-4.
28. Brutsche MH, Brutsche IC, Munawar M, Langley SJ, Masterson CM, Daley-Yates PT, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised cross-over study. Lancet 2000;356:556-61.
29. Pedersen S. Inhalers and nebulizers: which to choose and why? Respir Med 1996;90:69-77.
30. O'Byrne PM, Pedersen S. Measuring efficacy and safety of different inhaled corticosteroid preparations. J Allergy Clin Immunol 1998;102:879-86.
31. Cave A, Arlett P, Lee E. Inhaled and nasal corticosteroids: factors affecting the risks of systemic adverse effects. Pharmacol Ther 1999;83:153-79.
32. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy. A systematic review and meta-analysis. Arch Intern Med 1999;159:941-55.
33. Passalacqua G, Albano M, Canonica GW, Bachert C, Van Cauwenberge P, Davies RJ, et al. Inhaled and nasal corticosteroids: safety aspects. Allergy 2000;55:16-33.
34. Delacourt C. Faut-il avoir peur des corticoïdes inhalés chez l'enfant? Rev Fr Allergol Immunol Clin 2001;41:609-14.
35. Graham LM. Balancing safety and efficacy in the treatment of pediatric asthma. J Allergy Clin Immunol 2002;109S:560-6.
36. Skoner DP. Balancing safety and efficacy in pediatric asthma management. Pediatrics 2002;109:381-92.
37. Barnes NC, Hallett C, Harris TA. Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less. Respir Med 1998;92:95-104.
38. Affrime MB, Kosoglou T, Thonoor CM, Flannery BE, Herron JM. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest 2000;118:1538-46.
39. Stiksa GK, Nemcek K, Glennow C. Adrenal function in asthmatics treated with high-dose budesonide. Respiration 1985;48:91-3.
40. Maberly DJ, Gibson GJ, Butler AG. Recovery of adrenal function after substitution of beclomethasone dipropionate for oral corticosteroids. Br Med J 1973;1:778-9.
41. Zimmerman B, Gold M, Wherrett D, Hanna A. Adrenal suppression in two patients with asthma treated with low-doses of the inhaled steroid fluticasone propionate. J Allergy Clin Immunol 1998;101:425-6.
42. Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S. Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide. Eur Respir J 2002;20:127-33.
43. Hosking DJ. Effects of corticosteroids on bone turnover. Respir Med 1993;87S:15-20.
44. Picado C, Luengo M. Corticosteroid-induced bone loss. Prevention and management. Drug Saf 1996;15:347-59.
45. Reid DM. Methods of measurement of bone turnover and clinical evaluation of osteoporosis: relevance to asthma and corticosteroid therapy. Respir Med 1993;87S:9-13.
46. Ip M, Lam K, Yam L, Kung A, Ng M. Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest 1994;105:1722-7.
47. Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE. Cross-sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma. Thorax 1997;52:853-60.
48. Wong CA, Walsh LJ, Smith CJ, Wisniewski AF, Lewis SA, Hubbard R, et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 2000;355:1399-403.
49. Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol 1995;96:571-9.
50. Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J. Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss? Am J Respir Crit Care Med 1999;159:838-44.
51. Baraldi E, Bollini MC, De Marchi A, Zacchello F. Effect of beclomethasone dipropionate on bone mineral content assessed by X-ray densitometry in asthmatic children: a longitudinal evaluation. Eur Respir J 1994;7:710-4.
52. Luengo M, Del Rio L, Pons F, Picado C. Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study. Eur Respir J 1997;10:2110-3.
53. Elmstahl S, Ekstrom H, Galvard H, Johnell O, Gerhardsson-de Verdier M, Norjavaara E. Is there an association between inhaled corticosteroids and bone density in postmenopausal women? J Allergy Clin Immunol 2003;111:91-6.
54. Li JT, Ford LB, Chervinsky P, Weisberg SC, Kellerman D, Faulkner KG, et al.: Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma. J Allergy Clin Immunol 1999;103:1062-8.
55. Hughes JA, Conry BG, Male SM, Eastell R. One year prospective open study of the effect of high dose inhaled steroids, fluticasone propionate, and budesonide on bone markers and bone mineral density. Thorax 1999;54:223-9.
56. Matsumoto H, Ishihara K, Hasegawa T, Umeda B, Niimi A, Hino M. Effects of inhaled corticosteroid and short courses of oral corticosteroids on bone mineral density in asthmatic patients: a 4-year longitudinal study. Chest 2001;120:1468-73.
57. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001;345:941-7.
58. Allen DB. Systemic effects of intranasal steroids: an endocrinologist's perspective. J Allergy Clin Immunol 2000;106S:179-90.
59. McEvoy CE, Ensrud KE, Bender E, Genant HK, Yu W, Griffith JM, et al.: Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:704-9.
60. Hubbard RB, Smith CJP, Smeeth L, Harrison TW, Tattersfield AE. Inhaled corticosteroids and hip fracture. A population-based case-control study. Am J Respir Crit Care Med 2003;166:1563-6.
61. Van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001;16:581-8.
62. Jones A, Fay JK, Burr M, Stone M, Hood K, Roberts G. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002;1.
63. Hopp RJ, Degan JA, Phelan J, Lappe J, Gallagher GC. Cross-sectional study of bone density in asthmatic children. Pediatr Pulmonol 1995;20:189-92.
64. Martinati LC, Fay JK, Burr M, Stone M, Hood K, Roberts G. Longitudinal evaluation of bone mass in asthmatic children treated with inhaled beclomethasone dipropionate or cromolyn sodium. Allergy 1998;53:705-8.
65. Kinberg KA, Hopp RJ, Biven RE, Gallagher JC. Bone mineral density in normal and asthmatic children. J Allergy Clin Immunol 1994;94:490-7.
66. Allen HD, Thong IG, Clifton-Bligh P, Holmes S, Nery L, Wilson KB. Effects of high-dose inhaled corticosteroids on bone metabolism in prepubertal children with asthma. Pediatr Pulmonol 2000;29:188-93.
67. Boot AM, De Jongste JC, Verberne AA, Pols HA, De Muinck-Keizer-Schrama SM. Bone mineral density and bone metabolism of prepubertal children with asthma after long-term treatment with inhaled corticosteroids. Pediatr Pulmonol 1997;24:379-84.
68. Sharek PJ, Bergman DA. The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis. Pediatrics 2000;106:E8.
69. Price JF. Inhaled corticosteroids: clinical relevance of safety measures. Pediatr Pulmonol 1997;15S:40-5.
70. Allen DB, Mullen M, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol 1994;93:967-76.
71. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000;343:1054-63.
72. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000;343:1064-9.
73. Wolthers OD, Allen DB. Inhaled corticosteroids, growth, and compliance. N Engl J Med 2002;347:1210-1.
74. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997;337:8-14.
75. Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997;277:722-7.